Response to “Comment on: ‘FGF-23 and Long-Term Outcome in Peripheral Artery Disease’”
- 18 September 2026
- journal article
- letter
- Published by SAGE Publications in Angiology
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- FGF-23 and Long-term Outcome in Peripheral Artery DiseaseAngiology, 2025
- Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysisFrontiers in Cardiovascular Medicine, 2022
- Intact and C-Terminal FGF23 Assays—Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?The Journal of Clinical Endocrinology & Metabolism, 2020
- Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary SyndromeJAMA Cardiology, 2018
- Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-AnalysisJournal of the American Society of Nephrology, 2018
- Fibroblast Growth Factor‐23 and Frailty in Elderly Community‐Dwelling Individuals: The Cardiovascular Health StudyJournal of the American Geriatrics Society, 2016
- Fibroblast Growth Factor 23 and Cardiovascular Mortality after Kidney TransplantationClinical Journal of the American Society of Nephrology, 2013